Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54.8M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
13.7M
-
Shares change
-
+1.3M
-
Total reported value, excl. options
-
$127M
-
Value change
-
+$12.7M
-
Put/Call ratio
-
0.49
-
Number of buys
-
52
-
Number of sells
-
-36
-
Price
-
$9.29
Significant Holders of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) as of Q4 2016
115 filings reported holding CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2016.
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.7M shares
of 54.8M outstanding shares and own 25% of the company stock.
Largest 10 shareholders include RHO CAPITAL PARTNERS INC (3.07M shares), DISCIPLINED GROWTH INVESTORS INC /MN (888K shares), VANGUARD GROUP INC (787K shares), BlackRock Institutional Trust Company, N.A. (754K shares), BlackRock Fund Advisors (693K shares), Chescapmanager LLC (685K shares), FRANKLIN RESOURCES INC (592K shares), EverPoint Asset Management, LLC (500K shares), Opaleye Management Inc. (475K shares), and JPMORGAN CHASE & CO (367K shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.